Guangcheng Liu

Guangcheng Liu

Auto-generated profile, based on publicly available information

Guangcheng Liu

Department of Cardiology Medicine Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College Beijing China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2025 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
RZRuilin Zhou
Ruilin Zhou
QWQingyang Wu
Qingyang Wu
HQHao Qian
Hao Qian
LWLiang Wang
Liang Wang
GLGuangcheng Liu
Guangcheng Liu
SZShuyang Zhang
Shuyang Zhang
Background: About 20% of patients with coronary artery disease (CAD) experience adverse events within five years of undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction. In these patients, the impact of metformin on long-term prognosis remains uncertain. Methods: This study enrolled 22 metformin (Met)-CAD patients with diabetes mellitus (DM) who had been administered metformin for at least six months before PCI, 14 non-Met CAD-DM patients with DM who had never taken metformin or had stopped taking metformin for a year before PCI, and 22 matched healthy controls. A 5-year follow-up was conducted to collect clinical prognosis data. Fecal 16S rRNA sequencing and serum untargeted metabolomics analyses were performed. BugBase was utilized to analyze the possible functional changes in the gut microbiome. Multi-omics analysis was conducted using Spearman’s correlation to explore the interactions between metformin, gut microbiome, serum metabolites, and clinical prognosis. Results: Metformin significantly lowered the 5-year major adverse cardiac events (MACEs) in Met CAD-DM patients. We found a higher abundance of Bacteroides coprocola, Bacteroides massiliensis, Phascolarctobacterium succinatutens, and Eubacterium coprostanoligenes in the Met CAD-DM patients, as well as an increase in hydroxy-alpha-sanshool (HAS) and decenoylcarnitine and a decrease in tridec-10-enoic acid, Z-vad-fmk (benzyloxycarbonyl–Val–Ala–Asp (OMe)–fluoromethylketone), 3,9-dimethyluric acid in blood serum. Multi-omics analysis revealed that alterations in the gut microbiome and serum metabolites are significantly associated with the 5-year prognosis of CAD-DM. Conclusions: Metformin significantly improved the 5-year prognosis of CAD patients following PCI. Metformin tended to have more positive effects on the commensal flora and metabolic profiles, which may explain its beneficial effects on cardiovascular health. This study revealed the potential associations between metformin and the gut microbiome, an associated alteration in serum metabolome, and the impact on the host immune system and metabolic pathways.

13 October 2025 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
GLGuangcheng Liu
Guangcheng Liu
HZHaipeng Zhang
Haipeng Zhang
JZJingdai Zhang
Jingdai Zhang
HQHao Qian
Hao Qian
LWLiang Wang
Liang Wang
ZSZhujun Shen
Zhujun Shen
To verify the role of circular RNA circRftn1 in cardiac hypertrophy and elucidate its potential mechanism via the microRNA‐1192‐tripartite motif 25 and 41 (miR1192‐TRIM25/TRIM41) axis. A mouse model of cardiac hypertrophy was established via abdominal aortic coarctation surgery. An in vitro cell model was generated using neonatal mouse ventricular cardiomyocytes (NMVCs) co‐cultured with angiotensin II. Differentially expressed circular RNAs (circRNAs) were identified using next‐generation sequencing, and potential target microRNAs (miRNAs) and downstream messenger RNAs (mRNAs) were predicted using bioinformatic analysis. Reverse transcription quantitative polymerase chain reaction and western blotting were used to evaluate the expression of myocardial‐associated molecules at the transcriptional and translational levels, respectively. Expression of regulatory molecules was assessed after transfection with small interfering RNAs (siRNAs) or co‐culture with miRNA mimics. Dual‐luciferase reporter assays were performed to validate interactions between circRNAs and miRNAs. circRftn1 expression was significantly elevated both in vivo and in vitro. Concurrently, the expression of miR‐1192 was decreased, whereas its target mRNAs TRIM25 and TRIM41 were markedly upregulated. Knockdown of circRftn1 via siRNA transfection reversed cardiac hypertrophy and led to opposing expression trends of miR‐1192 and TRIM25/TRIM41. Dual‐luciferase reporter assays confirmed the sponge‐like interaction between circRftn1 and miR‐1192. By co‐culturing NMVCs with miR‐1192 mimics, its targets TRIM25/TRIM41 showed significant decreases. Moreover, NF‐κB signalling pathway appeared to be involved, as the expression of the p65 subunit paralleled that of circRftn1. circRftn1 may promote cardiac hypertrophy by modulating the miR‐1192‐TRIM25/TRIM41 axis and NF‐κB p65 pathway potentially serving as a downstream pathway.

15 December 2024 in Hellenic Journal of Cardiology
Verified
Journal Article
Open access
XLXinhao Li
Xinhao Li
XLXiaohang Liu
Xiaohang Liu
XFXiaojin Feng
Xiaojin Feng
TGTianchen Guo
Tianchen Guo
GLGuangcheng Liu
Guangcheng Liu
WCWei Chen
Wei Chen
Patients with advanced light chain cardiac amyloidosis (AL-CA) have a poor prognosis. We aimed to (1) assess the prognostic significance of all cardiac chamber longitudinal strains and (2) to further determine whether the combination of longitudinal strains with the Mayo staging system could provide additional prognostic value. Patients classified as Mayo 2012 stage III and IV were included in our study. We documented major adverse cardiac events (MACEs), including hospitalization for heart failure and all-cause mortality. Right ventricular free wall strain (RV-FWS), left ventricular global longitudinal strain (LV-GLS), left atrial longitudinal peak strain (LAPS), and right atrial longitudinal peak strain (RAPS) assessed using echocardiography. This research enrolled 140 advanced AL-CA patients, with 49.3% at Mayo 2012 stage IV. During follow-up, 84 patients developed MACEs. LV-GLS, RV-FWS, LAPS, and RAPS were independent risk factors for advanced AL-CA patients. Kaplan-Meier curves revealed that cutoff values of all heart chambers longitudinal strains had significant additional prognostic value for Mayo 2012 stage. According to multivariate Cox regression, Age, gender, Mayo2012, LAPS, RAPS, RV-FWS, and LV-GLS were included in the predictive Model. The AUCs of the Model were 0.887, 0.907, and 0.883 for 1-, 3-, and 5-year MACEs, respectively. The Model was internally validated using 200 bootstrapped resamples, yielding a corrected C-index of 0.810. A nomogram was developed and dynamically accessed via the following link: https://lxhadvancedalliexiantu.shinyapps.io/ALCA/. In patients with advanced AL-CA, it is essential to thoroughly evaluate all cardiac chamber longitudinal strains, particularly focusing on LV-GLS, RV-FWS, LAPS and RAPS.